Theodoros Tryfon: The landscape of pharmaceutical research and production is changing

 These developments will strengthen the position of our country in the field of pharmaceutical research and drug production, which today has 45 factories, represents approximately 10% of the European production network and has a competitive international presence in almost 150 countries of the world.

Greece aims to become a hub for pharmaceutical research and drug production in Europe. The investments already started by the Greek Pharmaceutical Industry will reach 1.5 billion euros by 2026 and include the upgrading of existing ones, but also the construction of 10 new factories throughout Greece with 56 production lines, 14 new research structures and the employment of 5,500 highly skilled workers.

 These developments will strengthen the position of our country in the field of pharmaceutical research and drug production, which today has 45 factories, represents approximately 10% of the European production network and has a competitive international presence in almost 150 countries of the world.

The completion of the investment program of the Greek pharmaceutical industries will cover 75% of the country’s pharmaceutical needs with quality treatments at an affordable cost for the system and the patient. This means ensuring the adequacy of the pharmaceutical market and drastically reducing shortages.

Europe after the pandemic realised that the research and production of drugs are critical infrastructures in order to ensure the adequacy of the pharmaceutical market and in this field today the Greek pharmaceutical industry is the protagonist, the president of the Panhellenic Pharmaceutical Industry Association, Theodoros Tryfon, said to Athens-Macedonian News Agency on Sunday. He described the ambitious investment plan of the Greek pharmaceutical industry, its actions to reverse brain drain into brain gain and makes proposals for pharmaceutical policy. He considers the main problem to be underfunding and emphasised that “adequate public funding will limit the unreasonable taxation of companies and will unlock even greater investments from the pharmaceutical industry, further increasing its competitiveness”.